ARBO-ZOONET is an international network financed by the European Commission's seventh framework program. The major goal of this initiative is capacity building for the control of emerging viral vector-borne zoonotic diseases, with a clear focus on West Nile virus, Rift Valley fever virus, and Crimean-Congo hemorrhagic fever virus. To evaluate the status quo of control measures against these viruses, an ARBO-ZOONET meeting was held in Istanbul, Turkey, from 19 to 20 November 2009. The symposium consisted of three themes: (1) vaccines: new and existing ones; (2) antivirals: existing and new developments; and (3) antivector vaccines. In addition, a satellite workshop was held on epidemiology and diagnosis. The meeting brought together foremost international experts on the subjects from both within and without the ARBO-ZOONET consortium. This report highlights selected results from these presentations and major conclusions that emanated from the discussions held.
Get full access to this article
View all access options for this article.
References
1.
AhmedJ, BouloyM, ErgönülÖ, FooksAet al.International network for capacity building for the control of emerging viral vector-borne zoonotic diseases: ARBO-ZOONET. Euro Surveill, 2009; 14pii:19160.
2.
Al-HazmiM, AyoolaEA, AbdurahmanM, BanzalSet al.Epidemic Rift Valley fever in Saudi Arabia: a clinical study of severe illness in humans. Clin Infect Dis, 2003; 36:245–252.
3.
AllenJR, HumphreysSJ. Immunisation of guinea pigs and cattle against ticks. Nature, 1979; 280:491–493.
4.
AlmeidaAP, BillingsleyPF. Induced immunity against the mosquito Anopheles stephensi (Diptera: Culicidae): effects of cell fraction antigens on survival, fecundity, and Plasmodium berghei (Eucoccidiida: Plasmodiidae) transmission. J Med Entomol, 2002; 39:207–214.
5.
AlmeidaAP, BillingsleyPF. Induced immunity against the mosquito Anopheles stephensi Liston (Diptera: Culicidae): effects on mosquito survival and fecundity. Int J Parasitol, 1998; 28:1721–1731.
6.
AndersonJF, RahalJJ. Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. Emerg Infect Dis, 2002; 8:107–108.
7.
AnderssonI, BladhL, Mousavi-JaziM, MagnussonKEet al.Human MxA protein inhibits the replication of Crimean-Congo hemorrhagic fever virus. J Virol, 2004; 78:4323–4329.
8.
AnderssonI, KarlbergH, Mousavi-JaziM, Martinez-SobridoLet al.Crimean-Congo hemorrhagic fever virus delays activation of the innate immune response. J Med Virol, 2008; 80:1397–1404.
9.
AnderssonI, LundkvistA, HallerO, MirazimiA. Type I interferon inhibits Crimean-Congo hemorrhagic fever virus in human target cells. J Med Virol, 2006; 78:216–222.
10.
BarnardBJ. Rift Valley fever vaccine—antibody and immune response in cattle to a live and an inactivated vaccine. J S Afr Vet Assoc, 1979; 50:155–157.
11.
BarnardBJ, BothaMJ. An inactivated rift valley fever vaccine. J S Afr Vet Assoc, 1977; 48:45–48.
12.
BarzonL, SquarzonL, CattaiM, FranchinEet al.West Nile virus infection in Veneto region, Italy, 2008–2009. Euro Surveill, 2009; 14pii:19289.
BergeronE, VincentMJ, NicholST. Crimean-Congo hemorrhagic fever virus glycoprotein processing by the endoprotease SKI-1/S1P is critical for virus infectivity. J Virol, 2007; 81:13271–13276.
15.
BillecocqA, GauliardN, Le MayN, ElliottRMet al.RNA polymerase I-mediated expression of viral RNA for the rescue of infectious virulent and avirulent Rift Valley fever viruses. Virology, 2008; 378:377–384.
16.
BirdBH, AlbarinoCG, HartmanAL, EricksonBRet al.Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. J Virol, 2008; 82:2681–2691.
17.
BirdBH, KsiazekTG, NicholST, MaclachlanNJ. Rift Valley fever virus. J Am Vet Med Assoc, 2009; 234:883–893.
18.
BlitvichBJ. Transmission dynamics and changing epidemiology of West Nile virus. Anim Health Res Rev, 2008; 9:71–86.
19.
BotrosB, OmarA, ElianK, MohamedGet al.Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine. J Med Virol, 2006; 78:787–791.
20.
BouloyM, FlickR. Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines. Antiviral Res, 2009; 84:101–118.
21.
BouloyM, JanzenC, VialatP, KhunHet al.Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs. J Virol, 2001; 75:1371–1377.
22.
BridgenA, ElliottRM. Rescue of a segmented negative-strand RNA virus entirely from cloned complementary DNAs. Proc Natl Acad Sci U S A, 1996; 93:15400–15404.
23.
Centers for Disease Control and Prevention. Viral hemorrhagic fever: initial management of suspected and confirmed cases. MMWR Morb Mortal Wkly Rep, 1983; 32:27S–38S.
24.
ChowersMY, LangR, NassarF, Ben-DavidDet al.Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerg Infect Dis, 2001; 7:675–678.
25.
ChuJJ, NgML. Interaction of West Nile virus with alpha v beta 3 integrin mediates virus entry into cells. J Biol Chem, 2004; 279:54533–54541.
26.
CoetzerJA. The pathology of Rift Valley fever. I. Lesions occurring in natural cases in new-born lambs. Onderstepoort J Vet Res, 1977; 44:205–211.
27.
de BoerSM, KortekaasJ, AntonisAF, KantJet al.Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge. Vaccine, 2010; 28:2330–2339.
28.
DempseyPW, AllisonME, AkkarajuS, GoodnowCCet al.C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science, 1996; 271:348–350.
29.
DiamondMS. Progress on the development of therapeutics against West Nile virus. Antiviral Res, 2009; 83:214–227.
30.
EasterdayBC. Rift valley fever. Adv Vet Sci, 1965; 10:65–127.
31.
EifanSA, ElliottRM. Mutational analysis of the Bunyamwera orthobunyavirus nucleocapsid protein gene. J Virol, 2009; 83:11307–11317.
32.
El GarchH, MinkeJM, RehderJ, RichardSet al.A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse. Vet Immunol Immunopathol, 2008; 123:230–239.
ErgönülÖ. Treatment of Crimean-Congo hemorrhagic fever. Antiviral Res, 2008; 78:125–131.
35.
ErgönülÖ, CelikbasA, DokuzoguzB, ErenSet al.Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin Infect Dis, 2004; 39:284–287.
36.
ErgönülÖ, WhitehouseCA. Crimean-Congo Hemorrhagic Fever: A Global Perspective. Dordrecht, The Netherlands: Springer, 2007.
37.
FauquetCM, MayoMA, ManiloffJ, DesselbergerUet al.Virus Taxonomy: Eighth Report of the International Committee on Taxonomy of Viruses. Academic Press, London: an imprint of Elsevier, 2005.
38.
FindlayGM, DaubneyR. The virus of Rift Valley fever or enzoötic hepatitis. Lancet, 1931; ii:1350–1351.
39.
FontenilleD, Traore-LamizanaM, DialloM, ThonnonJet al.New vectors of Rift Valley fever in West Africa. Emerg Infect Dis, 1998; 4:289–293.
40.
Frank-PetersideN. Response of laboratory staff to vaccination with an inactivated Rift Valley fever vaccine—TSI-GSD 200. Afr J Med Med Sci, 2000; 29:89–92.
41.
GarciaS, CranceJM, BillecocqA, PeinnequinAet al.Quantitative real-time PCR detection of Rift Valley fever virus and its application to evaluation of antiviral compounds. J Clin Microbiol, 2001; 39:4456–4461.
42.
GerrardSR, BirdBH, AlbarinoCG, NicholST. The NSm proteins of Rift Valley fever virus are dispensable for maturation, replication and infection. Virology, 2007; 359:459–465.
43.
GerrardSR, NicholST. Synthesis, proteolytic processing and complex formation of N-terminally nested precursor proteins of the Rift Valley fever virus glycoproteins. Virology, 2007; 357:124–133.
44.
GomesR, TeixeiraC, TeixeiraMJ, OliveiraFet al.Immunity to a salivary protein of a sand fly vector protects against the fatal outcome of visceral leishmaniasis in a hamster model. Proc Natl Acad Sci U S A, 2008; 105:7845–7850.
45.
GorchakovR, VolkovaE, YunN, PetrakovaOet al.Comparative analysis of the alphavirus-based vectors expressing Rift Valley fever virus glycoproteins. Virology, 2007; 366:212–225.
46.
GoughJM, KempDH. Localization of a low abundance membrane protein (Bm86) on the gut cells of the cattle tick Boophilus microplus by immunogold labeling. J Parasitol, 1993; 79:900–907.
47.
GranwehrBP, LillibridgeKM, HiggsS, MasonPWet al.West Nile virus: where are we now?Lancet Infect Dis, 2004; 4:547–556.
48.
GuyB, GuirakhooF, BarbanV, HiggsSet al.Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine, 2010; 28:632–649.
49.
HabjanM, PenskiN, SpiegelM, WeberF. T7 RNA polymerase-dependent and -independent systems for cDNA-based rescue of Rift Valley fever virus. J Gen Virol, 2008; 89:2157–2166.
50.
HabjanM, PenskiN, WagnerV, SpiegelMet al.Efficient production of Rift Valley fever virus-like particles: the antiviral protein MxA can inhibit primary transcription of bunyaviruses. Virology, 2009a. 385:400–408.
51.
HabjanM, PichlmairA, ElliottRM, OverbyAK. NSs protein of rift valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase. J Virol, 2009b. 83:4365–4375.
52.
HarringtonDG, LuptonHW, CrabbsCL, PetersCJet al.Evaluation of a formalin-inactivated Rift Valley fever vaccine in sheep. Am J Vet Res, 1980; 41:1559–1564.
53.
HayesCG. West Nile virus: Uganda, 1937, to New York City, 1999. Ann N Y Acad Sci, 2001; 951:25–37.
54.
HeiseMT, WhitmoreA, ThompsonJ, ParsonsMet al.An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus. Epidemiol Infect, 2009; 137:1309–1318.
55.
HoogstraalH. The epidemiology of tick-borne Crimean-Congo hemorrhagic fever in Asia, Europe, and Africa. J Med Entomol, 1979; 15:307–417.
56.
HugginsJW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis, 1989; 11:S750–S761.
57.
HunterP, ErasmusBJ, VorsterJH. Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep. Onderstepoort J Vet Res, 2002; 69:95–98.
58.
IkegamiT, NarayananK, WonS, KamitaniWet al.Dual functions of Rift Valley fever virus NSs protein: inhibition of host mRNA transcription and post-transcriptional downregulation of protein kinase PKR. Ann N Y Acad Sci, 2009a. 1171:E75–E85.
59.
IkegamiT, NarayananK, WonS, KamitaniWet al.Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation. PLoS Pathog, 2009b. 5:e1000287.
60.
IkegamiT, WonS, PetersCJ, MakinoS. Rescue of infectious rift valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene. J Virol, 2006; 80:2933–2940.
61.
IzadiS, SalehiM. Evaluation of the efficacy of ribavirin therapy on survival of Crimean-Congo hemorrhagic fever patients: a case-control study. Jpn J Infect Dis, 2009; 62:11–15.
62.
JordanI, BrieseT, FischerN, LauJYet al.Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells. J Infect Dis, 2000; 182:1214–1217.
63.
KamalSA. Pathological studies on postvaccinal reactions of Rift Valley fever in goats. Virol J, 2009; 6:94.
64.
KortekaasJ, DekkerA, de BoerSM, WeerdmeesterKet al.Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus. Vaccine, 2010; 28:2271–2276.
65.
KramerLD, LiJ, ShiPY. West Nile virus. Lancet Neurol, 2007; 6:171–181.
66.
KunzSE, KempDH. Insecticides and acaricides: resistance and environmental impact. Rev Sci Tech, 1994; 13:1249–1286.
67.
KutzlerMA, WeinerDB. DNA vaccines: ready for prime time?Nat Rev Genet, 2008; 9:776–788.
68.
LabudaM, TrimnellAR, LickovaM, KazimirovaMet al.An antivector vaccine protects against a lethal vector-borne pathogen. PLoS Pathog, 2006; 2:e27.
69.
LorenzoG, Martin-FolgarR, RodriguezF, BrunA. Priming with DNA plasmids encoding the nucleocapsid protein and glycoprotein precursors from Rift Valley fever virus accelerates the immune responses induced by an attenuated vaccine in sheep. Vaccine, 2008; 26:5255–5262.
70.
LowenAC, BoydA, FazakerleyJK, ElliottRM. Attenuation of bunyavirus replication by rearrangement of viral coding and noncoding sequences. J Virol, 2005; 79:6940–6946.
71.
MadaniTA, Al-MazrouYY, Al-JeffriMH, MishkhasAAet al.Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics. Clin Infect Dis, 2003; 37:1084–1092.
72.
MalinoskiFJ, HastySE, UsseryMA, DalrympleJM. Prophylactic ribavirin treatment of dengue type 1 infection in rhesus monkeys. Antiviral Res, 1990; 13:139–149.
73.
MandellRB, KoukuntlaR, MoglerLJ, CarzoliAKet al.A replication-incompetent Rift Valley fever vaccine: Chimeric virus-like particles protect mice and rats against lethal challenge. Virology, 2009; 397:187–198.
74.
MardaniM, JahromiMK, NaieniKH, ZeinaliM. The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Iran. Clin Infect Dis, 2003; 36:1613–1618.
75.
MartinJE, PiersonTC, HubkaS, RuckerSet al.A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis, 2007; 196:1732–1740.
76.
McElroyAK, AlbarinoCG, NicholST. Development of a RVFV ELISA that can distinguish infected from vaccinated animals. Virol J, 2009; 6:125.
77.
McIntoshBM, RussellD, dos SantosI, GearJH. Rift Valley fever in humans in South Africa. S Afr Med J, 1980; 58:803–806.
78.
MeeganJM. The Rift Valley fever epizootic in Egypt 1977–78. 1. Description of the epizootic and virological studies. Trans R Soc Trop Med Hyg, 1979; 73:618–623.
79.
MinkeJM, SigerL, KaracaK, AustgenLet al.Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge. Arch Virol Suppl, 2004; 18:221–230.
80.
MonathTP, LiuJ, Kanesa-ThasanN, MyersGAet al.A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci U S A, 2006; 103:6694–6699.
81.
MorreyJD, SmeeDF, SidwellRW, TsengC. Identification of active antiviral compounds against a New York isolate of West Nile virus. Antiviral Res, 2002; 55:107–116.
82.
MorrillJC, CarpenterL, TaylorD, RamsburgHHet al.Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep. Vaccine, 1991; 9:35–41.
83.
MorrillJC, JenningsGB, CaplenH, TurellMJet al.Pathogenicity and immunogenicity of a mutagen-attenuated Rift Valley fever virus immunogen in pregnant ewes. Am J Vet Res, 1987; 48:1042–1047.
84.
MorrillJC, MebusCA, PetersCJ. Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle. Am J Vet Res, 1997a. 58:1104–1109.
85.
MorrillJC, MebusCA, PetersCJ. Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids. Am J Vet Res, 1997b. 58:1110–1114.
86.
MoudyRM, MeolaMA, MorinLL, EbelGDet al.A newly emergent genotype of West Nile virus is transmitted earlier and more efficiently by Culex mosquitoes. Am J Trop Med Hyg, 2007; 77:365–370.
87.
MoutaillerS, KridaG, SchaffnerF, VazeilleMet al.Potential vectors of Rift Valley fever virus in the Mediterranean region. Vector Borne Zoonot Dis, 2008; 8:749–753.
88.
MullerR, SaluzzoJF, LopezN, DreierTet al.Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am J Trop Med Hyg, 1995; 53:405–411.
89.
NaslundJ, LagerqvistN, HabjanM, LundkvistAet al.Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus. Virology, 2009; 385:409–415.
90.
OzkurtZ, KikiI, ErolS, ErdemFet al.Crimean-Congo hemorrhagic fever in Eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy. J Infect, 2006; 52:207–215.
91.
PereraR, KhaliqM, KuhnRJ. Closing the door on flaviviruses: entry as a target for antiviral drug design. Antiviral Res, 2008; 80:11–22.
92.
PetersCJ, ReynoldsJA, SloneTW, JonesDEet al.Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator. Antiviral Res, 1986; 6:285–297.
93.
PittmanPR, LiuCT, CannonTL, MakuchRSet al.Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. Vaccine, 1999; 18:181–189.
94.
SallAA, ZanottoPM, SeneOK, ZellerHGet al.Genetic reassortment of Rift Valley fever virus in nature. J Virol, 1999; 73:8196–8200.
95.
SardelisMR, TurellMJ, DohmDJ, O'GuinnML. Vector competence of selected North American Culex and Coquillettidia mosquitoes for West Nile virus. Emerg Infect Dis, 2001; 7:1018–1022.
96.
SchmaljohnCS, ParkerMD, EnnisWH, DalrympleJMet al.Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins. Virology, 1989; 170:184–192.
97.
SchmaljohnCS, HooperJW. Bunyaviridae: the viruses and their replication. FieldsB.N., KnipeD.M., HowleyP.M., GriffinD.E.Fields Virology. Philadelphia: Lippincott Williams & Wilkins, 2001.
98.
Sharifi-MoodB, MetanatM, Ghorbani-VagheiA, Fayyaz-JahaniFet al.The outcome of patients with Crimean-Congo hemorrhagic fever in Zahedan, southeast of Iran: a comparative study. Arch Iran Med, 2009; 12:151–153.
99.
ShiX, ElliottRM. Generation and analysis of recombinant Bunyamwera orthobunyaviruses expressing V5 epitope-tagged L proteins. J Gen Virol, 2009; 90:297–306.
100.
SigerL, BowenRA, KaracaK, MurrayMJet al.Assessment of the efficacy of a single dose of a recombinant vaccine against West Nile virus in response to natural challenge with West Nile virus-infected mosquitoes in horses. Am J Vet Res, 2004; 65:1459–1462.
101.
SmithburnKC. Rift Valley fever; the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine. Br J Exp Pathol, 1949; 30:1–16.
102.
SmithburnKC, HaddowAJ, LumsdenWH. Rift Valley fever; transmission of the virus by mosquitoes. Br J Exp Pathol, 1949; 30:35–47.
Tasdelen FisginN, ErgönülÖ, DoganciL, TulekN. The role of ribavirin in the therapy of Crimean-Congo hemorrhagic fever: early use is promising. Eur J Clin Microbiol Infect Dis, 2009; 28:929–933.
105.
TignorGH, HanhamCA. Ribavirin efficacy in an in vivo model of Crimean-Congo hemorrhagic fever virus (CCHF) infection. Antiviral Res, 1993; 22:309–325.
106.
TurellMJ, DohmDJ, MoresCN, TerracinaLet al.Potential for North American mosquitoes to transmit Rift Valley fever virus. J Am Mosq Control Assoc, 2008; 24:502–507.
107.
WallaceDB, EllisCE, EspachA, SmithSJet al.Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever. Vaccine, 2006; 24:7181–7189.
108.
WattsDM, UsseryMA, NashD, PetersCJ. Inhibition of Crimean-Congo hemorrhagic fever viral infectivity yields in vitro by ribavirin. Am J Trop Med Hyg, 1989; 41:581–585.
WHO. Outbreaks of Rift Valley fever in Kenya, Somalia and United Republic of Tanzania. December 2006–April 2007. Wkly Epidemiol Rec, 2007b. 82:169–178.
112.
WilladsenP. Anti-tick vaccines in “Ticks, Disease and Control.”Parasitology, 2004; (Suppl),129:S367–S388.
113.
WilladsenP. The molecular revolution in the development of vaccines against ectoparasites. Vet Parasitol, 2001; 101:353–368.
114.
WilladsenP, BirdP, CobonGS, HungerfordJ. Commercialisation of a recombinant vaccine against Boophilus microplus. Parasitology, 1995; 110,Suppl:S43–S50.
115.
WilladsenP, RidingGA, McKennaRV, KempDHet al.Immunologic control of a parasitic arthropod. Identification of a protective antigen from Boophilus microplus. J Immunol, 1989; 143:1346–1351.
